12 Dec Gentian Diagnostics appoints Njaal Kind as Group CFO
Moss, 4 December 2017
Gentian Diagnostics AS (OSE: GENT-ME) is pleased to announce the appointment of Mr. Njaal Kind (46) as Group Chief Financial Officer. Mr. Kind holds a MSc from BI Norwegian Business School, and for the last four years he has served as the CFO for TiZir Ltd in London, England. Before that, Mr. Kind has been Business Analyst in Eramet Comilog Manganese in Paris, France (2009-2013) and Investment Director in Tinfos AS (2003-2009).
Mr. Kind’s experience and track-record within financial management, reporting, corporate governance and IR will be a strong addition to Gentian Diagnostics administration and management. Mr. Kind will commence in his new position on 2 January 2018.
Commenting on the news, CEO Bård Sundrehagen:
“We are pleased that we have been able to attract Njaal to our group management team. His expertise will complement the existing skills in the company and he will contribute to strengthening the finance/administrative function in a way that will improve the company in the direction that supports both our shareholders and employees’ interests.”
Commenting on the news, Njaal Kind:
“It is with great pleasure I take up the position as Group CFO of Gentian Diagnostics, and I look forward to joining a team of highly skilled people in a Company with a unique technology platform and significant growth ambitions.”
For further information, please contact:
CEO, Gentian Diagnostics AS
Cell Phone: +47 924 14 117
ABOUT GENTIAN DIAGNOSTICS AS
Gentian Diagnostics AS is a medical diagnostics company listed on Merkur Market, Oslo Stock Exchange with the ticker “GENT-ME”.
Gentian is headquartered in Moss, Norway, with a representative office in China and distribution subsidiaries in Sweden and USA.
Gentian designs, develops and markets in vitro diagnostic reagents (IVD) based on its proprietary Nanosense technology. The goal is to offer efficient and accurate reagents for major clinical chemistry platforms with a focus within the areas of kidney disease, cardiac disease, inflammation and veterinary medicine. The Nanosense technology will enable users to move assays from low volume immunology platforms to fully automated, high throughput instruments with shorter turnaround times, better workflow and improved cost efficiency.